AlphaFold predicted structure
OLFM2 · O95897

Mean pLDDT
83.7/ 100
Confident
454 residues
Confidence breakdown
- Very high(≥ 90)53%
- Confident(70–90)26%
- Low(50–70)12%
- Very low(< 50)9%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
olfactomedin 2
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Structural eye disease
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedAbnormality of the skeletal system
vertebral column disorder
liver disorder
esophageal disorder
musculoskeletal system disorder
metabolic dysfunction-associated steatotic liver disease
immune system disorder
obesity disorder
obesity due to melanocortin 4 receptor deficiency
Obesity
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Noelin-2
Involved in transforming growth factor beta (TGF-beta)-induced smooth muscle differentiation. TGF-beta induces expression and translocation of OLFM2 to the nucleus where it binds to SRF, causing its dissociation from the transcriptional repressor HEY2/HERP1 and facilitating binding of SRF to target genes (PubMed:25298399). Plays a role in AMPAR complex organization (By similarity). Is a regulator of vascular smooth-muscle cell (SMC) phenotypic switching, that acts by promoting RUNX2 and inhibiting MYOCD binding to SRF. SMC phenotypic switching is the process through which vascular SMCs undergo transition between a quiescent contractile phenotype and a proliferative synthetic phenotype in response to pathological stimuli. SMC phenotypic plasticity is essential for vascular development and remodeling (By similarity)
OLFM2 · O95897

Mean pLDDT
83.7/ 100
Confident
454 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0